
Eric Schadt, PhD
About Me
Eric Schadt, PhD, is Dean for Precision Medicine, Professor of Genetics and Genomic Sciences, and Mount Sinai Professor in Predictive Health and Computational Biology. He is also founder and CEO of Sema4, a Mount Sinai Venture
Dr. Schadt is an expert on the generation and integration of very large-scale sequence variation, molecular profiling and clinical data in disease populations for constructing molecular networks that define disease states and link molecular biology to physiology. He is known for calling for a shift in molecular biology toward a network-oriented view of living systems to complement the reductionist, single-gene approaches that currently dominate biology in order to more accurately model the complexity of biological systems. He has published more than 200 peer-reviewed papers in leading scientific journals, and contributed to a number of discoveries relating to the genetic basis of common human diseases such as diabetes, obesity, and Alzheimer’s disease.
Prior to joining Mount Sinai in 2011, he was Chief Scientific Officer at Pacific Biosciences. Previously, Dr. Schadt was Executive Scientific Director of Genetics at Rosetta Inpharmatics, a subsidiary of Merck & Co., and before Rosetta, Dr. Schadt was a Senior Research Scientist at Roche Bioscience. He received his B.A. in applied mathematics and computer science from California Polytechnic State University, his M.A. in pure mathematics from University of California, Davis, and his Ph.D. in bio-mathematics from University of California, Los Angeles (requiring Ph.D. candidacy in molecular biology and mathematics).
Language
English
Position
DEAN FOR PRECISION MEDICINE, PROFESSOR | Artificial Intelligence and Human Health, PROFESSOR | Genetics and Genomic Sciences
Research Topics
Bioinformatics, Computational Neuroscience, Epigenetics, Genetics, Human Genetics and Genetic Disorders
Video
Publications
Selected Publications
- A transcriptional program associated with neurotransmission in the living human brain. Alexander W. Charney, Lora E. Liharska, Eric Vornholt, Alissa Valentine, Anina Lund, Alice Hashemi, Ryan C. Thompson, Terry Lohrenz, Jessica S. Johnson, Nicole Bussola, Esther Cheng, You Jeong Park, Salman Qasim, Alisha Aristel, Lillian Wilkins, Kimia Ziafat, Hannah Silk, Lisa M. Linares, Brendan Sullivan, Claudia Feng, Seth R. Batten, Dan Bang, Leonardo S. Barbosa, Thomas Twomey, Jason P. White, Marina Vannucci, Beniamino Hadj-Amar, Emily Moya, Martijn Figee, Girish N. Nadkarni, Michael S. Breen, Kenneth T. Kishida, Joseph Scarpa, Eric E. Schadt, Ignacio Saez, P. Read Montague, Noam D. Beckmann, Brian H. Kopell. Molecular Psychiatry
- Real-world and Genomic data-based Asthma Insights through Network Analysis (REGAIN study): protocol for a novel retrospective and prospective longitudinal asthma cohort study. Andrew Kasarskis, Eileen Wang, Paul J. Bryce, Radoslav Savic, Qi Pan, Rachelle Weisman, Ellen Barnhart, Andrea Sifuentes, Eliseo Mosso, Lu Zhang, Eunjee Lee, Zhongyang Zhang, Ke Hao, Eric Schadt, Frank Nestle, Emanuele de Rinaldis, Linda Rogers. BMJ Open
- Establishing the relationship between brain cellular senescence and brain structure. Anina N. Lund, Brian H. Kopell, Negar Golestani, Eric Vornholt, Ryan C. Thompson, Lora E. Liharska, Yuyang Luo, Esther Cheng, You Jeong Park, Brian Fennessy, Lilian Wilkins, Deepak A. Kaji, Hannah Silk, Kimia Ziafat, Alice Hashemi, Emily Moya, Claudia Feng, Lisa M. Linares, Ariela Buxbaum Grice, Sabrina Xie, Marysia Kolbe Rieder, Joseph Scarpa, Prashant Kota, Vanessa Cohen, Brendan Sullivan, Punit Shah, Weiping Ma, Jessica S. Johnson, Gregory M. Miller, Richard Searfoss, Nischal Mahaveer Chand, Pei Wang, Girish N. Nadkarni, Niven R. Narain, Eric J. Nestler, Michael A. Kiebish, Eric E. Schadt, Alexander W. Charney, Noam D. Beckmann. Cell
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Schadt during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Equity
(Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)- Pathos
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.